Global Still’s
Disease Treatment Market, by Treatment (Pain Management, Corticosteroids,
Tocilizumab, Canakinumab, Anakinra, and Others), by Route of Administration
(Injectable and Oral), by Distribution Channel (Retail Pharmacies, Hospital
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be
valued at US$1,539.4 million in 2020 and is expected to exhibit a CAGR of 4.49%
during the forecast period (2020-2027), as highlighted in a new report published
by Coherent Market Insights.
Still’s disease is a rare
systemic inflammatory condition classified under polygenic autoinflammatory
disorder. The condition is characterized by persistent high spiking fever,
salmon colored skin rash, and arthralgia. Still’s disease is more commonly
observed in infants, known as systemic-onset juvenile idiopathic arthritis
(SOJIA) whereas, in adults, it is referred to as adult-onset Still’s disease
(AOSD). However, there is no single diagnostic test available for Still’s
disease. Diagnosis is typically done based on the observation of aforementioned
symptoms. Also, the treatment option for this condition is selected based on the
varying degree of symptoms.
Players in the market are focused
on research & development, drug approvals, and launching them in the
market, which is driving growth of the still’s disease treatment market.
Moreover, companies are focused on partnerships and joint agreements for the
development of novel therapies. For instance, in May 2019, Chugai
Pharmaceutical Co., Ltd. received expanded drug approval for adult-onset
Still's disease from the Ministry of Health Labor and Welfare in Japan for
Actemra (tocilizumab). Actemra is used for Still’s disease treatment.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/4023
Similarly, in April 2018, Swedish
Orphan Biovitrum AB received expanded approval from the European Commission
(EC) for Kineret (anakinra), which is an interleukin-1 receptor antagonist for
the treatment of Still’s Disease. Kineret was previously approved for
rheumatoid arthritis treatment. This approval expanded indication of anakinra
as well as addresses the significant unmet medical need among Still’s disease
patient population. Such factors are expected to strongly support growth of the
still’s disease treatment market.
Still’s Disease Treatment Market
- Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 outbreak has adversely
affected the still’s disease treatment market growth. It has become difficult
for the researchers to conduct researches during this COVID-19 pandemic. People
with Still's disease are at more risk to get infected with the COVID-19 virus.
Therefore, key players in this industry are focusing on developing strategies
to help patients to remain agile during the global disruptions due to the
pandemic crisis. Moreover, the government bodies of various countries are
taking initiatives to deal with the current chaos.
Browse 26 Market Data Tables and
28 Figures spread through 140 Pages and in-depth TOC on Still’s Disease
Treatment Market, By Treatment (Pain Management, Corticosteroids, Tocilizumab,
Canakinumab, Anakinra, and Others), By Route of Administration (Injectable and
Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and
Online Pharmacies), and By Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa)- Forecast to 2027"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/stills-disease-treatment-market-4023
The rise in funding for research
& development to develop novel treatment and therapies is a major factor
propelling growth of the global still’s disease treatment market. Moreover, the
emergence of drugs for the complications related to adult-onset still’s disease
treatment is another factor boosting the market growth. For instance, in June
2020, the U.S. Food and Drug Administration (FDA) approved the usage of
Canakinumab (Ilaris) in active still’s disease.
Key Takeaways of the Global Still’s
Disease Treatment Market:
The global still’s disease
treatment market is expected to exhibit a CAGR of 4.49% during the forecast
period (2020-2027), owing to collaborations and drug launches by market players
Among therapy types,
corticosteroid segment accounted for significant revenue share in the global
market. Corticosteroid therapy is started promptly with the dosage of 0.5–1
mg/kg/day, once the diagnosis is confirmed.
Major players operating in the
global still’s disease treatment market include AB2 Bio Ltd., Jubilant Life
Sciences Ltd, F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, Novartis
AG, Vintage Labs, Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals
PLC, Mylan N.V., Sun Pharmaceutical Industries Ltd, Horizon Therapeutics plc,
Zydus Cadila, Dr Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, and
Fresenius Kabi AG.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/4023
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment